Twin Tree Management
ESPR icon

Twin Tree Management’s Esperion Therapeutics ESPR Stock Holding History

Twin Tree Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-133
Closed -$6K – 1296
2019
Q2 		$6K Sell
133
-59
-31% -$2.77K ﹤0.01% 1134
2019
Q1 		$8K Buy
+192
New +$8.61K ﹤0.01% 1182

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Twin Tree Management's ESPR Position: Q3 2019 in Review

Twin Tree Management sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 133 shares — an estimated $6K sold.

Twin Tree Management first reported a position in ESPR in Q1 2019 and held it in 2 quarters. The position peaked at $8K in Q1 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Twin Tree Management reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Twin Tree Management sold 133 Esperion Therapeutics shares in Q3 2019, an estimated $6K.
  • Twin Tree Management first reported a position in Esperion Therapeutics in Q1 2019 and held it in 2 quarters.
  • Twin Tree Management's Esperion Therapeutics position peaked at $8K in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Twin Tree Management's 13F filing for Q3 2019, filed 12 Nov 2019.